1. Home
  2. ENVX vs AGIO Comparison

ENVX vs AGIO Comparison

Compare ENVX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$4.93

Market Cap

1.3B

Sector

Miscellaneous

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.80

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVX
AGIO
Founded
2006
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
ENVX
AGIO
Price
$4.93
$27.80
Analyst Decision
Buy
Buy
Analyst Count
9
8
Target Price
$13.61
$37.63
AVG Volume (30 Days)
5.3M
708.3K
Earning Date
05-21-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
40.94
N/A
EPS
N/A
N/A
Revenue
$31,821,000.00
$43,011,000.00
Revenue This Year
$40.85
$75.68
Revenue Next Year
$236.84
$167.63
P/E Ratio
N/A
N/A
Revenue Growth
37.91
N/A
52 Week Low
$4.67
$22.24
52 Week High
$16.49
$46.00

Technical Indicators

Market Signals
Indicator
ENVX
AGIO
Relative Strength Index (RSI) 34.41 46.37
Support Level N/A $26.48
Resistance Level $8.73 $29.49
Average True Range (ATR) 0.37 1.13
MACD 0.01 -0.17
Stochastic Oscillator 13.92 25.09

Price Performance

Historical Comparison
ENVX
AGIO

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: